Pure Global
NCT04480099

Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

The Efficacy and Safety of Targeted Drug in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma
Ruijin Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
CHOP for 6 cycles
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ruijin Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Jun 20, 2020
End date
Jun 20, 2024
Enrollment
106 participants
Primary outcome

Complete response rate

Summary

This prospective，multi-center，open-label, controlled study will evaluate the efficacy and
 safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral
 T-cell lymphoma.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04480099
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04480099 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ruijin Hospital and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 106 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.